a Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM) , Montréal , Qc , Canada.
b Division of Internal Medicine Department of Medicine , McGill University , Montreal , Qc , Canada.
Gut Microbes. 2019;10(3):424-428. doi: 10.1080/19490976.2018.1527167. Epub 2018 Oct 19.
Immunotherapy is widely used to treat a large variety of malignancies and has revolutionized the therapeutic approach to cancer. Major efforts are ongoing to identify biomarkers that predict response to immunotherapy as well as new strategies to improve ICI efficacy and clinical outcomes. Studies have shown that the gut microbiome determines the extent to which ICIs may invigorate the anticancer immune response. Here, the authors review recent studies that have described the effects of the gut microbiota on the efficacy of CTLA-4 and PD-1 inhibitors and outline potential future clinical directions of these findings.
免疫疗法被广泛用于治疗多种恶性肿瘤，并彻底改变了癌症的治疗方法。目前正在进行重大努力来确定预测免疫治疗反应的生物标志物，以及改善 ICI 疗效和临床结果的新策略。研究表明，肠道微生物组决定了 ICI 可能增强抗癌免疫反应的程度。在这里，作者回顾了最近描述肠道微生物群对 CTLA-4 和 PD-1 抑制剂疗效影响的研究，并概述了这些发现的潜在未来临床方向。
